X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DZD4205 (golidocitinib) is the first-in-class JAK1 only inhibitor approved in China in patients with relapsed or refractory peripheral T-Cell lymphoma.
Lead Product(s): Golidocitinib
Therapeutic Area: Oncology Product Name: DZD4205
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2024
Details:
DZD9008 (sunvozertinib) is an oral, potent, irreversible, & selective EGFR tyrosine kinase inhibitor. It is being evaluated for the treatment of Exon20ins-mutated locally advanced or metastatic NSCLC.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2024
Details:
DZD9008 (sunvozertinib) is an oral, potent, irreversible, & selective EGFR tyrosine kinase inhibitor. It is being evaluated for the treatment of Exon20ins-mutated locally advanced or metastatic NSCLC.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2024
Details:
DZD9008 (sunvozertinib) was designed as an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor. It is being evaluated for the treatment of Exon20ins-mutated locally advanced or metastatic non-small cell lung cancer.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Details:
DZD4205 (golidocitinib) is the first-in-class Janus kinase 1 (JAK1) only inhibitor currently being evaluated in a global, multicenter pivotal study (JACKPOT8 PARTB) in r/r PTCL.
Lead Product(s): Golidocitinib
Therapeutic Area: Oncology Product Name: DZD4205
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
DZD4205 (golidocitinib) is the first-in-class Janus kinase 1 (JAK1) only inhibitor currently being evaluated in a global, multicenter pivotal study (JACKPOT8 PARTB) in r/r PTCL.
Lead Product(s): Golidocitinib
Therapeutic Area: Oncology Product Name: DZD4205
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
The partnership aims to accelerate the development of DZD9008 (sunvozertinib), an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity, for patients with EGFR Exon20ins mutant NSCLC.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Anova Enterprises
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 06, 2023
Details:
DZD9008 (sunvozertinib) is an investigational, oral tyrosine kinase inhibitor (TKI) specifically designed to selectively target epidermal growth factor receptor (EGFR) exon20 insertion (exon20ins) mutations for the treatment of advanced NSCLC.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
DZD1516 was well tolerated at doses ≤ 250 mg, and in consistent with its high selectivity, no wild-type EGFR-related AEs have been reported. Thus, 250 mg was defined as MTD.
Lead Product(s): DZD1516,Trastuzumab,Capecitabine
Therapeutic Area: Oncology Product Name: DZD1516
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
DZD9008 (sunvozertinib) also demonstrated a favorable safety profile, Of all 277 patients in the safety set, the most common treatment-related adverse events were diarrhea and rash, the majority of which were Grade 1/2 and clinically manageable.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
